title: New targeted-colon delivery system: in vitro and in vivo evaluation using X-ray imaging.
abstract: The aim of this study was to formulate a new orally-administered colon delivery system of 5-flurouracil (5-FU) for the treatment of colon cancer. The system was designed to target 5-FU directly to the colon with high potential of much more effective and less toxic colon cancer treatment. The system was prepared by compression coating technique using granulated chitosan. The method was optimized by studying the effect of granulation and thickness of the coat with respect to the in vitro performance in a medium mimicking mouth-to-colon environment. The in vivo selectivity of the system was assessed by X-ray imaging technique using beagle dogs. Results showed that granulation of chitosan were effective in protecting against the known acid solubility of the polymer. Formula (F7) with coat weight of 50 mg/tablet exhibited the best protection profile with <10% of the drug released after 6 h. The resistance of the system to the simulated gastro-intestinal media was reduced as the chitosan coat weight decreases. The performance of the system in a rat caecal contents containing-medium showed that the susceptibility of this system for the enzymatic degradation by colonic enzymes. The X-ray imaging gave rise to the in vivo selectivity of this system for colon targeting by showing the resistivity of the system to the stomach and small intestine environment and the selective disintegration of the system inside the large bowel.
authors: Department of Pharmaceutics, College of Pharmacy, King Saud University, P.O. Box 2460, Riyadh 11451, Saudi Arabia. abyassin2002@yahoo.com
authors: Alaa Eldeen Bakry
authors: AE
authors: Yassin
authors: Ibrahim A
authors: IA
authors: Alsarra
authors: Fars K
authors: FK
authors: Alanazi
authors: Abdullah M
authors: AM
authors: Al-Mohizea
authors: Abdulrahman A
authors: AA
authors: Al-Robayan
authors: Omar A
authors: OA
authors: Al-Obeed
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D002626:Chemistry, Pharmaceutical / Q000379:methods; D048271:Chitosan / Q000737:chemistry; D003106:Colon / Q000201:enzymology / Q000378:metabolism*; D003110:Colonic Neoplasms / Q000188:drug therapy; D004285:Dogs; D016503:Drug Delivery Systems; D005079:Excipients / Q000737:chemistry; D005472:Fluorouracil / Q000008:administration & dosage* / Q000009:adverse effects; D041981:Gastrointestinal Tract / Q000000981:diagnostic imaging / Q000378:metabolism; D008297:Male; D011859:Radiography; D051381:Rats; D012995:Solubility; D013607:Tablets
chemical_list: D000964:Antimetabolites, Antineoplastic; D005079:Excipients; D013607:Tablets; D048271:Chitosan; D005472:Fluorouracil